Monolaurin for EBV and ME/CFS: Benefits, Evidence, and Dosage
What Is Monolaurin?
Monolaurin has antiviral activity against some enveloped viruses in laboratory studies, but oral monolaurin has not been shown in human clinical trials to treat Epstein-Barr virus, ME/CFS, or viral reactivation. Most of the evidence comes from cell experiments and animal studies.
Monolaurin is a monoglyceride, a compound formed when glycerol is combined with lauric acid. Lauric acid is a medium-chain fatty acid (MCT) that is found abundantly in coconut oil and, to a lesser extent, in palm kernel oil and human breast milk.
Monolaurin, also called glycerol monolaurate, is a compound formed from glycerol and lauric acid. Lauric acid occurs naturally in coconut oil, palm kernel oil, and human breast milk. The body may form some monolaurin during digestion, but consuming lauric acid is not equivalent to taking a measured dose of supplemental monolaurin.. This transformation significantly enhances its biological activity, especially in terms of its antimicrobial properties.
Monolaurin’s chemical structure allows it to disrupt the lipid membranes (cell membranes or cell walls) of various microorganisms, including bacteria, viruses, and fungi, making it a powerful agent for supporting the immune system.
If you're interested in the broader role supplements may play in postviral illness, see my guide to supplements for long COVID (PASC) and ME/CFS.
💡 Looking for quick answers? Jump to the FAQ
How Does Monolaurin Kill Viruses?
Generally, what sets viruses apart is whether they have a fat (lipid) bilayer membrane on the outside (enveloped viruses) or lack one (non-enveloped viruses). Examples of enveloped viruses include influenza, Epstein-Barr virus (EBV), human cytomegalovirus (CMV), human herpes virus (HHV6), respiratory syncytial virus (RSV), and human coronaviruses (SARS-CoV-2).
As a counter-example, Parvovirus B19 is non-enveloped. This virus has also been implicated in ME/CFS onset and progression. Enveloped viruses are more susceptible to heat and dryness than non-enveloped viruses.
In laboratory studies, monolaurin can interact with the lipid envelope surrounding certain viruses. At sufficient concentrations, it can make the envelope leak or disintegrate, which can prevent the virus from remaining infectious. This activity has been demonstrated outside the human body in cell-culture experiments. It has not been established that taking monolaurin orally produces the same antiviral concentrations in human tissues.
Disruption of the envelope can render the viral particles noninfectious.
In an observational metabolomics study of Italian healthcare workers, higher circulating monolaurin levels were associated with a lower likelihood of SARS-CoV-2 infection. This does not show that monolaurin supplementation prevents infection, because the study did not assign participants to take monolaurin or establish cause and effect.
Can You Get Enough Monolaurin From Coconut Oil?
The most significant natural source of lauric acid, and consequently monolaurin, is coconut oil. Coconut oil contains about 50% lauric acid, making it an excellent source for deriving monolaurin. However, to obtain therapeutic levels of monolaurin, one would need to consume large quantities of coconut oil, which isn’t always practical or advisable due to its high caloric content. Some suggest it may be upwards of 100-300 mL of coconut oil per day to achieve therapeutic levels of monolaurin. Said another way, you would need to take 6.5 teaspoons (32 mL) of coconut oil to achieve the amount of monolaurin in one 600mg capsule. Impractical!
Coconut Oil:
The richest natural source of lauric acid, used to produce monolaurin.
Palm Kernel Oil:
Another source, though less common and with a lower lauric acid content.
Human Breast Milk:
Contains lauric acid, providing infants with natural protection against infections during early development.
In a 2024 randomized controlled trial, hospitalized COVID-19-infected patients were given 3 tablespoons (44 mL) per day of coconut oil (this contained 47.96% lauric acid). However, this provided no clear benefit to the virus progression and made no changes in inflammatory markers. Simply consuming coconut oil is not practical nor effective for a therapeutic antiviral approach. Only a highly concentrated monolaurin supplement makes sense.
What Human Studies Have Found
Human evidence is extremely limited. A review of monolaurin as a dietary supplement found no peer-reviewed clinical evidence that orally administered monolaurin treats infections in humans. Most antiviral evidence comes from laboratory studies, while oral animal research has largely involved livestock infections. Pig studies can help explore mechanisms, but their findings cannot establish that oral monolaurin treats human viral infections.
One study showed that monolaurin supplementation in pigs infected with the encapsulated virus (PEDV), which is a coronavirus family virus, inhibited the virus from replicating and stimulated the interferon pathway. The interferon pathway is a defense mechanism where cells produce proteins called interferons that help stop viruses from spreading by signaling other cells to boost their antiviral defenses.
In another study of piglets, supplementing the diet with monolaurin decreased systemic inflammation and improved intestinal permeability. The gut microflora composition was also affected, with fewer “bad” bacteria.
Is There Evidence for Monolaurin in ME/CFS or EBV?
Antiviral drugs commonly prescribed for ME/CFS have shown limited effectiveness. It follows that alternatives to these medications should be considered to tackle the chronic infections common to the condition, particularly Epstein Barr (EBV).
Monolaurin’s significance lies in its broad-spectrum antimicrobial properties. It has been studied for its ability to inactivate a wide range of pathogens, including bacteria, viruses, and fungi, without harming beneficial gut flora. This makes it a valuable tool in supporting immune health and protecting against infections in ME/CFS. It is one I successfully take myself when I feel viral reactivation and one I’ve recommended to other patients for years. Some die-off reaction is likely. One may start with a low dose and gradually increase to roughly 3g per day. Up to 9g of monolaurin per day is the maximum dose but rarely needed.
Monolaurin Side Effects and Liver Safety
Monolaurin is widely sold as a dietary supplement, but its safety has not been well studied at the gram-level doses commonly recommended online. A review of the clinical literature found no peer-reviewed trials evaluating oral monolaurin as an antimicrobial supplement in humans. This means we do not have reliable data on its long-term effects, ideal dose, medication interactions, or safety in people with chronic illness. Most published safety information comes from laboratory research, animal studies, or the use of glycerol monolaurate as a food ingredient rather than as a high-dose supplement.
There is currently no strong evidence that monolaurin routinely damages the liver. However, the absence of reported liver injury is not the same as proof that long-term, high-dose use is safe. Human studies have not adequately tracked liver enzymes or other adverse effects in people taking concentrated oral monolaurin over time.
Reported reactions to monolaurin supplements may include digestive upset, nausea, loose stools, headache, fatigue, or worsening of existing symptoms. These effects are not well characterized in clinical trials, and new symptoms should not automatically be interpreted as a Herxheimer or “die-off” reaction. They may instead reflect intolerance, an excessive dose, another ingredient in the product, or an unrelated fluctuation in illness.
Extra caution is appropriate for people who:
have liver or gallbladder disease
have abnormal liver-test results
take several medications or supplements
are pregnant or breastfeeding
have severe ME/CFS or a history of reacting strongly to supplements
Anyone who develops persistent nausea, abdominal pain, dark urine, pale stools, jaundice, itching, or unusual fatigue after starting monolaurin should stop taking it and seek medical advice. Because the human evidence is so limited, monolaurin should not be described as proven safe for indefinite daily use.
-
Monolaurin, also called glycerol monolaurate, is a compound made from glycerol and lauric acid. Lauric acid occurs naturally in coconut oil, palm kernel oil, and human breast milk. Supplemental monolaurin is a concentrated form and should not be assumed to have the same effects as eating coconut oil.
-
In laboratory studies, monolaurin can disrupt the lipid envelope surrounding certain viruses. Damage to this envelope may prevent the viral particle from remaining infectious. This effect has primarily been demonstrated in cell experiments, however, and it is not known whether oral supplementation produces comparable antiviral concentrations in human tissues.
-
Coconut oil is rich in lauric acid, but it does not provide a predictable equivalent dose of monolaurin. The body may convert some lauric acid into monolaurin, but the amount is uncertain. Human trials have also not established coconut oil as an effective antiviral treatment.
-
There are currently no human clinical trials showing that oral monolaurin treats ME/CFS, long COVID, Epstein-Barr virus reactivation, or other proposed chronic viral infections. Most supporting evidence comes from laboratory and animal studies. A review of the clinical literature found no peer-reviewed evidence supporting oral monolaurin as an antimicrobial dietary supplement in humans.
-
No evidence-based dose has been established for ME/CFS, long COVID, EBV, or chronic viral reactivation. Supplement labels and practitioner protocols vary, but these regimens have not been validated in clinical trials. People with ME/CFS may also be sensitive to supplements, so starting with large doses or escalating automatically is not advisable.
-
A true Jarisch–Herxheimer reaction is a specific inflammatory response most commonly associated with antibiotic treatment of certain bacterial infections. New symptoms after taking monolaurin should not automatically be interpreted as microbial “die-off.” They may reflect an adverse effect, intolerance, dose-related reaction, or ordinary symptom fluctuation.
-
There is not enough human research to establish the long-term liver safety of high-dose oral monolaurin. Published human studies are sparse and largely involve topical rather than oral use. Anyone with liver disease, abnormal liver tests, multiple medications, or new symptoms after starting it should discuss its use with a clinician.
-
No. Monolaurin has not been shown to replace prescription antiviral treatment. Anyone being treated for an active or clinically significant viral infection should not stop or substitute prescribed medication without speaking with the prescribing clinician.
-
Choose a product that clearly states the amount of monolaurin per serving and provides independent quality testing when available. Avoid products that rely primarily on proprietary blends or promise to eliminate chronic viral infections. Product quality does not establish that monolaurin is effective for ME/CFS, long COVID, or EBV.
-
There is no evidence-based timeline because oral monolaurin has not been shown in clinical trials to treat ME/CFS, long COVID, or EBV reactivation. Personal reports of improvement cannot determine whether monolaurin caused the change or how quickly someone else might respond.
-
Laboratory research suggests that lipid-disrupting compounds may inactivate some enveloped viruses, and EBV is an enveloped virus. However, there is no human clinical evidence showing that oral monolaurin reduces EBV viral activity, prevents reactivation, or treats EBV-associated symptoms.
References
Thormar H, Isaacs CE, Brown HR, Barshatzky MR, Pessolano T. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob Agents Chemother. 1987;31(1):27-31. doi:10.1128/AAC.31.1.27
Barberis E, Amede E, Tavecchia M, et al. Understanding protection from SARS-CoV-2 using metabolomics. Sci Rep. 2021;11(1):13796. Published 2021 Jul 5. doi:10.1038/s41598-021-93260-2
Alejandria MM, Dalmacio LMM, Climacosa FMM, et al. Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients in a Tertiary Referral Hospital: A Randomized Controlled Trial. Acta Med Philipp. 2024;58(8):31-41. Published 2024 May 15. doi:10.47895/amp.vi0.7498
Liu Z, Zhu L, Zhao X, et al. Effects of oral of administration of monoglycide laurate on virus load and inflammation in PEDV infected porcine. Front Vet Sci. 2022;9:980381. Published 2022 Oct 13. doi:10.3389/fvets.2022.980381
Zhang Q, Yi D, Ji C, et al. Monolaurin Confers a Protective Effect Against Porcine Epidemic Diarrhea Virus Infection in Piglets by Regulating the Interferon Pathway. Front Immunol. 2022;12:797476. Published 2022 Jan 13. doi:10.3389/fimmu.2021.797476
Wei K, Yang X, Zhao H, Chen H, Bei W. Effects of combined application of benzoic acid and 1-monolaurin on growth performance, nutrient digestibility, gut microbiome and inflammatory factor levels in weaned piglets. Porcine Health Manag. 2023;9(1):46. Published 2023 Oct 19. doi:10.1186/s40813-023-00339-5
Barker LA, Bakkum-Gamez JN, Yao Y, et al. The clinical use of monolaurin as a dietary supplement. J Chiropr Med. 2020;19(3):174-182. doi:10.1016/j.jcm.2020.05.004
Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg. 2017;96(1):46-52. doi:10.4269/ajtmh.16-0434
